Stockreport

Bavarian Nordic Announces Initiation of Phase 2 Trial of BN-Brachyury for the Treatment of Chordoma

BAVARIAN NORDIC R/I S/ADR  (BVNRY) 
NASDAQ:AMEX Investor Relations: bavarian-nordic.com/investor.aspx
PDF First dose has been administered in the multiple-center study BN-Brachyury for the treatment of chordoma received FDA Orphan Drug Designation in May 2018  COPENHAGEN [Read more]